…
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
| Net income | -162.45M | -129.47M | -96.66M | -102.59M | -70.89M |
| Selling general administrative | 21.00M | 17.74M | 18.82M | 24.71M | 20.39M |
| Selling and marketing expenses | - | - | 0.38M | - | - |
| Gross profit | - | -0.39M | -0.38M | - | - |
| Reconciled depreciation | 0.49M | 0.39M | 0.39M | 0.36M | 0.16M |
| Ebit | -162.45M | -129.47M | -96.66M | -107.34M | -71.49M |
| Ebitda | -161.96M | -129.08M | -96.28M | -106.99M | -71.10M |
| Depreciation and amortization | 0.49M | 0.39M | 0.38M | 0.36M | 0.40M |
| Non operating income net other | - | - | - | 2.20M | 0.40M |
| Operating income | -178.70M | -142.26M | -104.96M | -106.99M | -71.49M |
| Other operating expenses | 178.70M | 142.26M | 104.96M | 106.99M | 71.49M |
| Interest expense | - | - | - | 0.36M | 0.23M |
| Interest income | 16.22M | 12.68M | 5.75M | 2.23M | 0.44M |
| Net interest income | 16.22M | 12.68M | 5.75M | 2.23M | 0.44M |
| Income tax expense | - | -0.00M | - | -2.20M | -0.21M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 178.70M | 142.26M | 104.96M | 106.99M | 71.49M |
| Cost of revenue | - | 0.39M | 0.38M | - | - |
| Total other income expense net | 16.25M | 12.78M | 8.31M | 2.20M | 0.40M |
| Net income from continuing ops | -162.45M | -129.47M | -96.06M | -104.79M | -71.10M |
| Net income applicable to common shares | - | - | - | -104.79M | -71.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M |
| Intangible assets | - | 0.68M | - | - | - |
| Other current assets | 5.96M | 2.27M | 4.03M | 4.48M | 0.22M |
| Total liab | 54.87M | 42.02M | 23.05M | 18.10M | 11.38M |
| Total stockholder equity | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M |
| Other current liab | 41.42M | 36.09M | 17.93M | 15.16M | 0.38M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -597.56M | -435.11M | -305.63M | -208.98M | -104.19M |
| Other assets | - | - | 0.00M | 2.77M | 0.54M |
| Cash | 48.30M | 139.48M | 68.54M | 23.70M | 287.25M |
| Total current liabilities | 51.80M | 41.76M | 21.62M | 16.55M | 9.02M |
| Current deferred revenue | - | - | - | - | 7.69M |
| Net debt | -47.11M | -138.05M | -66.12M | -21.14M | -283.96M |
| Short term debt | 1.12M | 1.17M | 0.99M | 1.01M | 0.93M |
| Short long term debt total | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Other stockholder equity | 1075.49M | 843.92M | 559.18M | 408.33M | 388.90M |
| Property plant equipment | - | - | - | 1.48M | 4.72M |
| Total current assets | 515.45M | 438.47M | 266.51M | 208.90M | 287.25M |
| Net tangible assets | - | - | - | 197.55M | 284.57M |
| Short term investments | 457.14M | 294.61M | 193.27M | 180.72M | 273.44M |
| Net receivables | 4.06M | 2.12M | 0.67M | 0.32M | 0.13M |
| Long term debt | 3.00M | - | - | - | - |
| Inventory | - | -4.02M | - | -0.32M | - |
| Accounts payable | 9.25M | 4.46M | 2.70M | 0.37M | 0.02M |
| Accumulated other comprehensive income | 0.62M | 0.14M | 0.35M | -1.81M | -0.15M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -208.98M | -104.19M |
| Non currrent assets other | 16.83M | 9.76M | 8.14M | 2.77M | 3.98M |
| Non current assets total | 17.98M | 12.51M | 10.43M | 6.75M | 8.70M |
| Capital lease obligations | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -155.76M | -93.53M | 42.40M | 91.84M | -273.86M |
| Change to liabilities | - | - | - | 7.37M | -0.68M |
| Total cashflows from investing activities | -155.76M | -93.53M | -4.85M | 91.48M | -275.44M |
| Net borrowings | 3.00M | 0.00M | - | - | - |
| Total cash from financing activities | 211.30M | 268.82M | 133.41M | 0.48M | 1.39M |
| Change to operating activities | - | - | - | 2.67M | 3.51M |
| Net income | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
| Change in cash | -91.18M | 70.94M | 44.84M | 9.89M | -324.74M |
| Begin period cash flow | 139.48M | 68.54M | 23.70M | 13.81M | 338.55M |
| End period cash flow | 48.30M | 139.48M | 68.54M | 23.70M | 13.81M |
| Total cash from operating activities | -146.72M | -104.35M | -83.73M | -82.06M | -50.69M |
| Issuance of capital stock | 205.39M | 266.29M | 129.74M | - | 0.00M |
| Depreciation | 0.49M | 0.39M | 0.38M | 0.36M | 0.16M |
| Other cashflows from investing activities | - | -0.16M | 0.01M | - | - |
| Sale purchase of stock | 1.03M | - | - | 0.48M | 1.39M |
| Other cashflows from financing activities | 211.30M | 2.53M | 3.68M | 0.15M | 0.67M |
| Change to netincome | - | - | - | 18.83M | 17.41M |
| Capital expenditures | 0.00M | 0.16M | 0.00M | 0.36M | 1.57M |
| Cash flows other operating | - | - | - | -3.05M | 0.17M |
| Cash and cash equivalents changes | - | - | - | 9.89M | -324.74M |
| Change in working capital | 2.77M | 9.16M | -0.59M | 3.02M | 2.83M |
| Stock based compensation | 17.59M | 22.58M | 17.26M | 18.83M | 15.91M |
| Other non cash items | -5.12M | -7.02M | -4.12M | 0.51M | 1.22M |
| Free cash flow | -146.72M | -104.51M | -83.73M | -82.43M | -52.27M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals Inc |
- -% |
7.02 | - | - | - | 2.09 | -3.33 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Sean P. Bohen M.D., Ph.D. | Pres, CEO & Director | 1967 |
| Mr. Shane William Charles Kovacs M.B.A. | Chief Operating & Financial Officer | 1974 |
| Dr. Cyrus L. Harmon Ph.D. | Chief Research Officer & Director | 1971 |
| Mr. Kinney Horn | Chief Bus. Officer | 1974 |
| Dr. Peter J. Kushner Ph.D. | Co-Founder & Sr. Research Fellow | 1939 |
| Ms. Courtney Dugan | VP of Investor Relations & Communications | NA |
| Mr. John B. Moriarty Jr. | Exec. VP, Chief Legal Officer & Corp. Sec. | 1968 |
| Ms. Julie Dexter | VP & Head of People | NA |
| Dr. David C. Myles Ph.D. | Chief Discovery & Non-Clinical Devel. Officer | 1963 |
| Ms. Demiana Faltaos Ph.D., Pharm.D. | VP & Head of Clinical Pharmacology | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.